Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2025-12-30 @ 5:09 PM
Study NCT ID:
NCT01399203
Status:
UNKNOWN
Last Update Posted:
2011-08-03
First Post:
2011-07-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
Sponsor:
Guangdong Provincial People's Hospital
Organization:
Study Overview
Official Title:
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
Status:
UNKNOWN
Status Verified Date:
2010-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONVIN
Brief Summary:
To investigate the predictive value of the contrast media volume to creatinine clearance (V/CrCl) ratio for the risk of contrast-induced nephropathy (CIN) (i.e., within 48-72 h) and to determine a relatively safe V/CrCl cut-off value to avoid CIN in patients following PCI
Detailed Description:
contrast media volume to creatinine clearance (V/CrCl) ratios were obtained from consecutive consenting patients after unselective PCI. Receiver-operator characteristic (ROC) curves were used to identify the optimal sensitivity for the observed range of V/CrCl. The predictive value of V/CrCl for the risk of CIN was assessed using multivariate logistic regression.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: